These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

784 related items for PubMed ID: 33357641

  • 1. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR, Aggarwal RK, Rao NS, Billa G, Kumar S.
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [Abstract] [Full Text] [Related]

  • 2. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD, Claggett B, Desai AS, Packer M, Zile M, Swedberg K, Rouleau JL, Shi VC, Starling RC, Kozan Ö, Dukat A, Lefkowitz MP, McMurray JJ.
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hemodynamic Effects of Sacubitril-Valsartan Versus Enalapril in Patients With Heart Failure in the EVALUATE-HF Study: Effect Modification by Left Ventricular Ejection Fraction and Sex.
    Mitchell GF, Solomon SD, Shah AM, Claggett BL, Fang JC, Izzo J, Abbas CA, Desai AS, EVALUATE-HF Investigators*.
    Circ Heart Fail; 2021 Mar; 14(3):e007891. PubMed ID: 33663237
    [Abstract] [Full Text] [Related]

  • 5. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD, Vaduganathan M, L Claggett B, Packer M, Zile M, Swedberg K, Rouleau J, A Pfeffer M, Desai A, Lund LH, Kober L, Anand I, Sweitzer N, Linssen G, Merkely B, Luis Arango J, Vinereanu D, Chen CH, Senni M, Sibulo A, Boytsov S, Shi V, Rizkala A, Lefkowitz M, McMurray JJV.
    Circulation; 2020 Feb 04; 141(5):352-361. PubMed ID: 31736342
    [Abstract] [Full Text] [Related]

  • 6. Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF.
    Ehteshami-Afshar S, Mooney L, Dewan P, Desai AS, Lang NN, Lefkowitz MP, Petrie MC, Rizkala AR, Rouleau JL, Solomon SD, Swedberg K, Shi VC, Zile MR, Packer M, McMurray JJV, Jhund PS, Hawkins NM.
    J Am Heart Assoc; 2021 Feb 16; 10(4):e019238. PubMed ID: 33522249
    [Abstract] [Full Text] [Related]

  • 7. Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.
    Curtain JP, Adamson C, Docherty KF, Jhund PS, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV.
    JACC Heart Fail; 2023 Jul 16; 11(7):749-759. PubMed ID: 37407154
    [Abstract] [Full Text] [Related]

  • 8. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM.
    JACC Heart Fail; 2020 Jan 16; 8(1):43-54. PubMed ID: 31838035
    [Abstract] [Full Text] [Related]

  • 9. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial.
    Chandra A, Lewis EF, Claggett BL, Desai AS, Packer M, Zile MR, Swedberg K, Rouleau JL, Shi VC, Lefkowitz MP, Katova T, McMurray JJV, Solomon SD.
    JAMA Cardiol; 2018 Jun 01; 3(6):498-505. PubMed ID: 29617523
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of Sacubitril/Valsartan in High-Risk Patients in the PIONEER-HF Trial.
    Berg DD, Samsky MD, Velazquez EJ, Duffy CI, Gurmu Y, Braunwald E, Morrow DA, DeVore AD.
    Circ Heart Fail; 2021 Feb 01; 14(2):e007034. PubMed ID: 33530704
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The AWAKE-HF Study: Sacubitril/Valsartan Impact on Daily Physical Activity and Sleep in Heart Failure.
    Khandwalla RM, Grant D, Birkeland K, Heywood JT, Fombu E, Owens RL, Steinhubl SR, AWAKE-H. F. Study Investigators.
    Am J Cardiovasc Drugs; 2021 Mar 01; 21(2):241-254. PubMed ID: 32978755
    [Abstract] [Full Text] [Related]

  • 14. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD, Braunwald E, Morrow DA, Duffy CI, Ambrosy AP, Chakraborty H, McCague K, Rocha R, Velazquez EJ, PIONEER-HF Investigators.
    JAMA Cardiol; 2020 Feb 01; 5(2):202-207. PubMed ID: 31825471
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
    Velazquez EJ, Morrow DA, DeVore AD, Duffy CI, Ambrosy AP, McCague K, Rocha R, Braunwald E, PIONEER-HF Investigators.
    N Engl J Med; 2019 Feb 07; 380(6):539-548. PubMed ID: 30415601
    [Abstract] [Full Text] [Related]

  • 18. A randomized clinical trial on the short-term effects of 12-week sacubitril/valsartan vs. enalapril on peak oxygen consumption in patients with heart failure with reduced ejection fraction: results from the ACTIVITY-HF study.
    Halle M, Schöbel C, Winzer EB, Bernhardt P, Mueller S, Sieder C, Lecker LSM.
    Eur J Heart Fail; 2021 Dec 07; 23(12):2073-2082. PubMed ID: 34591356
    [Abstract] [Full Text] [Related]

  • 19. Outcomes and Effect of Treatment According to Etiology in HFrEF: An Analysis of PARADIGM-HF.
    Balmforth C, Simpson J, Shen L, Jhund PS, Lefkowitz M, Rizkala AR, Rouleau JL, Shi V, Solomon SD, Swedberg K, Zile MR, Packer M, McMurray JJV.
    JACC Heart Fail; 2019 Jun 07; 7(6):457-465. PubMed ID: 31078482
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Safety of Sacubitril/Valsartan by Dose Level Achieved in the PIONEER-HF Trial.
    Berg DD, Braunwald E, DeVore AD, Lala A, Pinney SP, Duffy CI, Gurmu Y, Velazquez EJ, Morrow DA.
    JACC Heart Fail; 2020 Oct 07; 8(10):834-843. PubMed ID: 32800511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.